C. Robert Horsburgh Jr, MD
Professor of Epidemiology
Boston University School of Public Health
Dept of Epidemiology

MD, Case Western Reserve University
MS, Yale University



Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Department of Biostatistics, the Department of GLobal Health and the Department of Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS and the Epidemiology of Tuberculosis. His research focuses on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS. Currently, he is involved in research in Brazil, India, Peru, South Africa and Tanzania. He has served as the National Steering Committee Co-Chairman of the Tuberculosis Trials Consortium and the Tuberculosis Epidemiologic Studies Consortium. He is currently the Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials (www.resisttb.org). His office is located in the Center for Global Health and Development at BU School of Public Health.

Professor
Boston University School of Public Health
Department of Global Health


Professor
Boston University School of Medicine
Department of Medicine
Infectious Diseases Section

Professor
Boston University School of Public Health
Department of Biostatistics


Boston Medical Center



2015 International Union Against Tuberculosis and Lung Disease, North American Region: Lifetime Achievement Award
2011 Boston University School of Public Health: Faculty Career Award in Research and Scholarship
2011 CDC: Excellence in Public Health Impact Award


Phase 2 Pharmacodynamic Study of High-dose Levofloxacin inMDR-TB Treatment
08/01/2016 - 07/31/2018 (PI)
NIH/National Institute of Allergy & Infectious Diseases
4U01AI100805-04

The impact of Alcohol Consumption on TB Treatment Outcomes
04/08/2016 - 03/31/2018 (PI)
Boston Medical Center Corporation NIH NIAID
5R01AI119037-02

Tuberculosis Trials Consortium
10/01/2014 - 09/30/2017 (PI)
Veterans Affairs Medical Center of Washington DC HHS CDC

Biomarkers for Risk of TB and for TB Treatment Failure and Relapse
10/02/2013 - 09/15/2017 (PI)
Boston Medical Center Corporation National Science Fdn

Autophagy-based HDT for Tuberculosis
09/25/2015 - 08/31/2017 (PI)
University of New Mexico NIH NIAID
5UH2AI122313-02

Impact of Pregnancy on Tuberculosis
08/25/2015 - 07/31/2017 (PI)
Boston Medical Center Corporation NIH NIAID
R01AI124217-02

Biomarkers and mechanisms of Paucibacillary and Latent Tuberculosis
08/01/2014 - 07/31/2017 (PI)
Boston Medical Center Corporation NIH NIAID
5U19AI111276-03

Lifespan/Tufts/brown Center for AIDS Research (CFAR): Core K, Core B, and Core G
07/01/2016 - 06/30/2017 (PI)
The Miriam Hospital NIH NIAID
4P30AI042853-19

Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
06/15/2012 - 05/31/2017 (PI)
Boston Medical Center Corporation NIH NIDA
5R01DA031059-03

Tuberculosis Research Institute at MUHAS
02/01/2016 - 01/31/2017 (PI)
Dartmouth College Medical School NIH FIC
4D43TW009573-04

Showing 10 of 23 results. Show All Results

BU Clinical HIV/AIDS Research Training Program
08/01/2016 - 07/31/2021 (PI)
NIH-NIAID
2T32AI052074-11A1

Lifespan/Tufts/brown Center for AIDS Research (CFAR): Core K Clinical Sciences Core
07/01/2016 - 06/30/2017 (PI)
Miriam Hospital NIH-NIAID

BU Clinical HIV/AIDS Research Training Program
08/02/2010 - 07/31/2016 (PI)
NIH-NIAID
5T32AI052074-10

Boston Community Partnership Against HIV
09/30/2002 - 09/29/2005 (PI)
DHHS-Office Minority Hlth

History Of Hepatitis C Infecti
09/30/1999 - 06/30/2005 (PI)
NIH-NIDDK
5 R01 DK56410-05 & Supplement



Yr Title Project-Sub Proj Pubs
2016 Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment 4U01AI100805-04
2016 BU Clinical HIV/AIDS Research Training Program 2T32AI052074-11A1 27
2016 Biomarkers of Persistent TB Infection and TB Treatment Relapse 5U19AI111276-03-7767 3
2016 Clinical Core 5U19AI111276-03-7772 3
2015 Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment 5U01AI100805-03
2015 Biomarkers of Persistent TB Infection and TB Treatment Relapse 5U19AI111276-02-7767 3
2015 Clinical Core 5U19AI111276-02-7772 3
2014 Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment 5U01AI100805-02
2014 BU Clinical HIV/AIDS Research Training Program 5T32AI052074-10 27
2014 Biomarkers of Persistent TB Infection and TB Treatment Relapse 1U19AI111276-01-7767 3
Showing 10 of 39 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017 Mar 15. PMID: 28344011; DOI: 10.1016/S2213-2600(17)30079-6;.
  2. McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis. 2017 Mar; 56:194-199.View Related Profiles. PMID: 27955992; DOI: 10.1016/j.ijid.2016.11.423;.
  3. Galea S, Horsburgh CR. The Unnecessary Persitence of Tuberculosis. The Huffington Post. 2016.
  4. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP. Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. J Int AIDS Soc. 2016; 19(1):20987.View Related Profiles. PMID: 27677395; DOI: 10.7448/IAS.19.1.20987;.
  5. Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.View Related Profiles. PMID: 27548695; PMCID: PMC4993510; DOI: 10.1371/journal.pone.0161469;.
  6. Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016; 11(5):e0155968. PMID: 27223622; PMCID: PMC4880345; DOI: 10.1371/journal.pone.0155968;.
  7. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4. PMID: 27046707; PMCID: PMC4843774; DOI: 10.5588/ijtld.15.0490;.
  8. Hochberg NS, Rekhtman S, Burns J, Ganley-Leal L, Helbig S, Watts NS, Brandeis GH, Ellner JJ, Horsburgh CR. The complexity of diagnosing latent tuberculosis infection in older adults in long-term care facilities. Int J Infect Dis. 2016 Mar; 44:37-43.View Related Profiles. PMID: 26802447; DOI: 10.1016/j.ijid.2016.01.007;.
  9. Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis. 2016 Jan; 20(1):24-42. PMID: 26688526; DOI: 10.5588/ijtld.15.0221;.
  10. Horsburgh, C. R., Rusen I. D., and Mitnick C. D. Optimizing MDR-TB clinical trials: insights from the first global MDR-TB clinical trials landscape meeting. The International Journal of Tuberculosis and Lung Disease. 2016; 20:S1-S3.
Showing 10 of 159 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 159 publications over 34 distinct years, with a maximum of 14 publications in 2011

YearPublications
19831
19852
19864
19871
19884
19898
19902
19912
19926
19939
19945
19954
19964
19975
19982
19994
20006
20012
20024
20033
20043
20052
20068
20073
20086
20091
201011
201114
20123
20135
20145
201510
20169
20171
Contact for Mentoring:


715 Albany St Talbot Building
Boston MA 02118
Google Map


Horsburgh's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department